 Treatment with the immunosuppressive drug mycophenolate mofetil MMF may result in gastrointestinal GI complications in some patients. This study will investigate the safety and tolerability of converting kidney transplant recipients with gastrointestinal symptoms from their current treatment of mycophenolate mofetil MMF to treatment with enteric-coated mycophenolate sodium EC-MPS. 